Table 2

Changes in the clinical, laboratory and imaging parameters over 24 weeks in patients with active AS (n=20) treated with ustekinumab in the TOPAS trial

ParameterBaselineWeek 24p Value
ASDAS (mean±SD)3.0±0.62.0±1.10.001
BASDAI, points NRS (mean±SD)5.3±1.53.0±1.8<0.001
BASFI, points NRS (mean±SD)5.3±1.93.0±2.3<0.001
BASMI (mean±SD)1.6±1.41.2±1.30.016
Chest expansion, cm3.7±1.94.4±2.10.032
Patient global6.3±1.63.3±2.3<0.001
Physician global5.9±1.32.4±1.9<0.001
General pain6.5±1.63.3±2.4<0.001
Nocturnal pain6.5±1.93.3±2.4<0.001
MASES Enthesitis Score (mean±SD)3.1±3.52.5±3.90.326
SPARCC Enthesitis Index (mean±SD)2.9±3.42.6±3.00.195
Swollen joint count, range 0–64 (mean±SD)0.1±0.40.1±0.20.330
ASAS NSAIDs intake score (mean±SD)68.7±37.933.3±33.60.008
CRP, mg/L5.9±5.56.4±7.10.760
ESR, mm/h20.0±18.516.9±18.20.308
Sacroiliac Joints Osteitis Score (mean±SD)*5.4±4.93.2±3.40.026
Spine Osteitis Score (mean±SD)*4.1±3.62.8±3.00.041
  • *Berlin MRI scores, calculated for n=17 patients with complete sets of images.

  • AS, ankylosing spondylitis; ASAS, Assessment of SpondyloArthritis International Society; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, AS quality of life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C reactive protein; ESR, erythrocyte sedimentation rate; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; NRS, numeric rating scale; NSAIDs, non-steroidal anti-inflammatory drugs; SPARCC, Spondyloarthritis Research Consortium of Canada.